Literature DB >> 1009680

Specific antibody-dependent killing of Toxoplasma gondii by normal macrophages.

S E Anderson, S C Bautista, J S Remington.   

Abstract

The requirement for specificity of antibody-dependent inhibition or killing of intracellular Toxoplasma gondii trophozoites by normal mouse peritoneal macrophages was evaluated in vitro using light microscopy and autoradiography. Anti-toxoplasma antibody in the presence of 'accessory factor' rendered extracellular T. gondii trophozoites non-viable and non-infectious for cells, whereas exposure of extracellular trophozoites to heat-inactivated immune serum did not appear to damage the parasites. Although pretreatment of extracellular trophozoites with heat-inactivated immune serum neither diminished nor prevented infection of normal mouse peritoneal macrophages, it did confer upon macrophages the ability to inhibit or kill the organisms once they were intracellular. In contrast, pretreatment of trophozoites with either heat-inactivated normal or Besnoitia jellisoni immune serum did not enable normal macrophages to inhibit or kill T. gondii; rather, such organisms multiplied intracellularly in normal macrophages. Thus, pretreatment with specific antibody alone prepared T. gondii trophozoites for intracellular destruction by normal mouse peritoneal macrophages. These results suggest that spesific antibody acting in concert with normal macrophages may play a role in controlling infection with T. gondii.

Entities:  

Mesh:

Year:  1976        PMID: 1009680      PMCID: PMC1540976     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Adoptive immunity to intracellular infection.

Authors:  J K Frenkel
Journal:  J Immunol       Date:  1967-06       Impact factor: 5.422

2.  Scanning electron microscopy of Toxoplasma gondii.

Authors:  A S Klainer; J L Krahenbuhl; J S Remington
Journal:  J Gen Microbiol       Date:  1973-03

3.  Mechanisms of immunity in typhus infections. 3. Influence of human immune serum and complement on the fate of Rickettsia mooseri within the human macrophages.

Authors:  M R Gambrill; C L Wisseman
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

4.  The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii.

Authors:  J L Krahenbuhl; J Ruskin; J S Remington
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

5.  IgM antibodies in acute toxoplasmosis. II. Prevalence and significance in acquired cases.

Authors:  J S Remington; M J Miller; I Brownlee
Journal:  J Lab Clin Med       Date:  1968-05

6.  Serum-mediated immune cellular responses to Brucella melitensis REV 1. II. Restriction of Brucella by immune sera and macrophages.

Authors:  D J Ralston; S S Elberg
Journal:  J Reticuloendothel Soc       Date:  1969-04

7.  Immunity to Toxoplasma gondii induced in vitro in non-immune mouse macrophages with specifically immune lymphocytes.

Authors:  K K Sethi; B Pelster; N Suzuki; G Piekarski; H Brandis
Journal:  J Immunol       Date:  1975-10       Impact factor: 5.422

8.  Effect of antithymocyte serum on experimental toxoplasmosis in mice.

Authors:  O Strannegård; E Lycke
Journal:  Infect Immun       Date:  1972-05       Impact factor: 3.441

9.  Effect of normal and activated human macrophages on Toxoplasma gondii.

Authors:  S E Anderson; J S Remington
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

10.  Assessment in vitro of immunity against Toxoplasma gondii.

Authors:  T C Jones; L Len; J G Hirsch
Journal:  J Exp Med       Date:  1975-02-01       Impact factor: 14.307

View more
  24 in total

1.  Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting.

Authors:  Nicole Joller; Stefan S Weber; Andreas J Müller; Roman Spörri; Petra Selchow; Peter Sander; Hubert Hilbi; Annette Oxenius
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-03       Impact factor: 11.205

2.  Survival of immunoglobulin G-opsonized Toxoplasma gondii in nonadherent human monocytes.

Authors:  C E Fadul; J Y Channon; L H Kasper
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Specific and nonspecific mediation of protective immunity to Toxoplasma gondii.

Authors:  L Reyes; J K Frenkel
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

4.  Human dendritic cell activity against Histoplasma capsulatum is mediated via phagolysosomal fusion.

Authors:  Lucy A Gildea; Georgianne M Ciraolo; Randal E Morris; Simon L Newman
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice.

Authors:  Lawrence L Johnson; Peter C Sayles
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  BALB/c mice resistant to Toxoplasma gondii infection proved to be highly susceptible when previously infected with Myocoptes musculinus fur mites.

Authors:  Aurea Welter; José Roberto Mineo; Deise Aparecida de Oliveira Silva; Elaine Vicente Lourenço; Eloísa Amália Vieira Ferro; Maria Cristina Roque-Barreira; Neide Maria da Silva
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

7.  CD4+ T cells in the pathogenesis of murine ocular toxoplasmosis.

Authors:  Fangli Lu; Shiguang Huang; Lloyd H Kasper
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Effect of alveolar macrophages on Toxoplasma gondii.

Authors:  F W Ryning; J S Remington
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

9.  Gamma interferon production, but not perforin-mediated cytolytic activity, of T cells is required for prevention of toxoplasmic encephalitis in BALB/c mice genetically resistant to the disease.

Authors:  Xisheng Wang; Hoil Kang; Takane Kikuchi; Yasuhiro Suzuki
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Effect of cyclophosphamide on Toxoplasma gondii infection: reversal of the effect by passive immunization.

Authors:  A Hafizi; F Z Modabber
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.